First it helped in the fight against Covid, now Derby firm is behind new trial to detect monkeypox in 10-minute test
A NEW lateral flow test to detect monkeypox infections in humans in 10 minutes is being trialled with the help of UK businesses including Derby life science firm SureScreen Diagnostics.
The company is working with Yorkshire-based medical technology provider TestCard and Guy’s and St Thomas’ NHS Foundation Trust in London to carry out the trial.
During the pandemic, SureScreen was involved in some of the first Covid-19 flow tests to be made in the UK. The monkeypox test uses a small drop of finger-prick blood, and is said to be the first of its kind in Europe.
As of June 22, 2022, the Government said there was 846 laboratoryconfirmed cases of monkeypox in the UK and it has been declared as a notifiable disease by the UK Health Security Agency.
It is spread through close contact with an infected person and symptoms can include a high temperature, headache, muscle aches, backache, swollen glands, shivering, exhaustion and, usually, later a rash.
It is currently diagnosed by a PCR test with a viral swab taken from a patient’s skin by a clinician, which must then be sent to the laboratory for testing. SureScreen said its system uses a rapid diagnostic device with a digital reader app that can be done at home.
SureScreen Diagnostics director David Campbell said: “We’re extremely grateful to be working with such a great team at Guy’s and St Thomas’ on this ground-breaking work in developing a rapid lateral flow antibody test that can be used to help monitor and understand the spread of monkeypox throughout the UK and further afield.
“We don’t expect monkeypox to be an issue anything like what Covid-19 has been, but as we learnt during the early stages of Covid-19 it is critical that quality testing is put in place quickly so we can better understand the nature and spread of the disease. This work also demonstrates yet another example of how lateral flow technology can play such a critical part in healthcare across the world outside of Covid-19 and it will help us to improve healthcare in the future.”
It said it has the potential to inform clinicians much quicker about the spread of the disease via TestCard’s ClearScreen app and, if successful, the tests could be ready for deployment within a couple of months.
The monkeypox trials are the latest in an ongoing partnership between the three organisations, which worked together on developing lateral flow tests and digital reading applications for Covid-19.
SureScreen said its Covid-19 antigen LFTs were the first European tests to pass the validation process in the laboratory by Public Health England last year and, as well as being used as part of the UK Government’s rapid testing programme, are being exported to around 60 countries worldwide.
Dr Rahul Batra managing director of technologies and innovations lead at the Centre for Clinical Infection and Diagnostics Research at Guy’s and St Thomas’ NHS Foundation Trust, said: “While monkeypox does not spread easily and there is currently not a need for mass community testing, the Covid-19 pandemic has shown us that emerging infectious diseases require rapid diagnostics development, effective surveillance and health information systems capable of using point of care diagnostic data for rapid and effective interventions.
“Building on the previous successful collaboration with our diagnostics and digital technologies partners SureScreen and TestCard we have been able to quickly develop and begin trialling a new point-ofcare test for monkeypox antibodies.
“Our hope is that this test and others like it that we have in development will provide a mechanism to assist clinicians with rapid identification of cases, clusters, and the sources of infection sooner than previously possible, in order to provide optimal clinical care to patients and prevent further transmissions.”
SureScreen said anyone who has a new rash with blisters or has been in close or sexual contact with someone who has or might have monkeypox – even if they have still to be tested – in the past three weeks, or who has been to West or Central Africa in the past three weeks, should visit a sexual health clinic.
As we learnt during the early stages of Covid-19 it is critical that quality testing is put in place quickly. David Campbell